Trazodone: What to Expect, Week-by-Week First Month

What Trazodone Is and How It Works

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder (MDD) since 1981 [1]. At low doses (25 to 100 mg), its strong H1 histamine receptor antagonism and 5-HT2A blockade dominate, producing sedation. At higher doses (150 to 400 mg), serotonin reuptake inhibition adds antidepressant activity. This dose-dependent pharmacology explains why the sleep and mood timelines diverge.

Mechanism at Low vs. High Dose

At 50 mg, trazodone binding to H1 and alpha-1 adrenergic receptors accounts for nearly all clinical effect. A 2018 receptor-occupancy review published in CNS Drugs confirmed that 5-HT2A antagonism and H1 blockade are saturated at doses below 100 mg, while serotonin transporter (SERT) occupancy reaches meaningful levels only above 150 mg [2]. Prescribers therefore treat 50 mg trazodone at bedtime as a sedative-hypnotic, and 150 mg or higher as an antidepressant.

Why Off-Label Sleep Use Became So Common

Trazodone became one of the most prescribed off-label sleep aids in the United States. A 2005 analysis by Mendelson in the Journal of Clinical Psychiatry noted that trazodone was already the most commonly prescribed medication for insomnia despite limited large randomized controlled trial (RCT) support for that indication at the time [3]. The appeal: no DEA scheduling, no dependence liability, and a low acquisition cost relative to newer sleep agents.

Week 1: Days 1 to 7

Week one is dominated by sedation, orthostatic effects, and adjustment. Sleep typically improves before mood.

Sleep Effects in the First Seven Days

Low-dose trazodone (50 to 100 mg) reduces sleep latency and increases total sleep time within the first one to three nights for most patients. A crossover RCT published in Sleep (N=16 patients with primary insomnia) found that trazodone 50 mg significantly increased slow-wave sleep and reduced wake time after sleep onset compared with placebo (P<0.05), with benefit apparent on night one [4]. Patients taking trazodone for MDD at higher doses report a similar early-night sedation effect even before mood improves.

Sedation and Dizziness: Peak Risk Window

Daytime grogginess ("hangover effect"), dizziness, and orthostatic hypotension are most pronounced in days 1 to 7. Rising slowly from bed, avoiding alcohol, and timing the dose 30 to 60 minutes before lights-out reduces fall risk. These effects typically attenuate by the end of week two as the body adjusts to alpha-1 blockade. Driving and operating machinery should be approached with caution during week one.

Antidepressant Activity at Week 1

Antidepressant response at week one is minimal. At a starting dose of 75 to 150 mg per day, SERT occupancy is low, and serotonergic remodeling has not yet occurred. Patients beginning trazodone for MDD should expect little mood change during this window.

Week 2: Days 8 to 14

By day eight, sedation side effects begin to decrease for most patients. Prescribers often consider a first dose increase during this window.

Side Effect Trajectory

Dry mouth, blurred vision, and daytime sedation typically fall from moderate to mild between days 8 and 14. A systematic review in Journal of Affective Disorders (2019, 12 trials, N=1,282) reported that dropouts due to adverse events clustered heavily in the first seven days and declined sharply by day 14 [5]. Patients who reach the two-week mark without intolerable side effects generally continue treatment successfully.

Dose Titration for Depression

For MDD, standard titration moves from a starting dose of 75 to 150 mg per day to 150 to 200 mg per day at week two if the initial dose is tolerated. The FDA-approved prescribing information allows upward adjustment of 50 mg every 3 to 4 days as tolerated, targeting 150 to 400 mg per day in outpatients [1]. Splitting the dose, with the larger portion taken at bedtime, helps manage daytime sedation while maintaining therapeutic exposure.

Sleep at Week 2

Objective improvements in sleep architecture often consolidate by week two. Trazodone increases stage N3 (slow-wave) sleep percentage and reduces nighttime awakenings. A polysomnography study by Yamadera et al. (Psychiatry and Clinical Neurosciences, 1998, N=10) showed that after two weeks of trazodone 50 mg, N3 sleep increased from a mean of 14.2% to 22.8% of total sleep time [6].

Week 3: Days 15 to 21

Week three is when the first signals of antidepressant efficacy may appear, particularly improvements in sleep quality, appetite, and energy, which often precede mood improvement.

Early Antidepressant Signals

Energy, appetite normalization, and concentration improvements often emerge before subjective mood lifts. This pattern mirrors other antidepressants and is thought to reflect early noradrenergic and serotonergic changes in prefrontal circuits. Patients should be counseled that these vegetative symptoms improving before mood is expected, not a sign of treatment failure.

Monitoring at the Three-Week Mark

A scheduled check-in at three weeks allows the prescriber to assess tolerability, measure functional improvement, and decide whether a further dose increase is needed. For MDD, if the patient tolerates 150 mg per day without meaningful symptom change, a titration to 200 to 300 mg per day is appropriate. The American Psychiatric Association's Practice Guideline for the Treatment of Patients With Major Depressive Disorder (3rd edition) recommends reassessing dose adequacy at 2 to 4 weeks and increasing to the maximum tolerated dose before switching agents [7].

Orthostatic Hypotension: Still a Watch Point

Orthostatic dizziness may recur with each dose increase. Blood pressure checks in the first few days after any upward titration help identify patients at risk, particularly those over 65 or those on concurrent antihypertensives.

Week 4: Days 22 to 30

Week four is the milestone window for judging early antidepressant response. Most guidelines define a partial response as a 25 to 50% reduction in symptom scores.

Defining Response vs. Remission

Response to an antidepressant is conventionally defined as a 50% or greater reduction from baseline on the Hamilton Depression Rating Scale (HAMD-17) or the PHQ-9. Remission is defined as a HAMD-17 score below 7 or a PHQ-9 score below 5. A 2005 Cochrane-style meta-analysis of trazodone for depression found response rates of 47 to 62% at 4 to 6 weeks in RCTs meeting minimum quality criteria, comparable to first-generation tricyclic antidepressants but with a more favorable cardiac profile [8].

Sleep at Week 4

For patients using low-dose trazodone specifically for insomnia, week four typically represents stable, sustained benefit. The AASM Clinical Practice Guideline for Chronic Insomnia (2017) notes that the evidence base for trazodone in chronic insomnia consists largely of short-term trials, and long-term RCT data beyond eight weeks remain sparse [9]. Patients and clinicians should schedule a reassessment at the 4-week mark to confirm ongoing benefit and the absence of tolerance.

Full Therapeutic Dose Context

By week four, most outpatients prescribed trazodone for MDD will be at 200 to 300 mg per day. Hospitalized patients may reach 400 mg per day under closer monitoring. The ceiling dose is 600 mg per day in inpatients per the prescribing label [1], though doses above 400 mg are rarely used in outpatient practice due to limited additional efficacy and increased adverse event risk.

Side Effect Reference Guide: Weeks 1 to 4

Understanding when specific adverse effects peak and resolve makes it easier to distinguish expected adjustment from a reason to call the prescriber.

Common Side Effects and Their Typical Timeline

| Side Effect | Peak Window | Typical Resolution | |---|---|---| | Daytime sedation | Days 1 to 7 | Weeks 2 to 3 | | Dizziness / lightheadedness | Days 1 to 10 | Weeks 2 to 3 | | Dry mouth | Days 1 to 14 | Persists in some patients | | Blurred vision | Days 1 to 14 | Weeks 2 to 4 | | Nausea | Days 1 to 7 | Week 2 | | Headache | Days 1 to 5 | Week 1 to 2 | | Orthostatic hypotension | Days 1 to 7, with each dose increase | Variable |

Rare but Serious Adverse Events

Priapism (prolonged, painful erection unrelated to sexual stimulation) occurs in approximately 1 in 6,000 male patients taking trazodone and has been reported as early as the first week of treatment [1]. Any erection lasting more than two hours requires immediate emergency evaluation. The risk is not clearly dose-dependent and may occur at low sleep doses.

Serotonin syndrome is possible, particularly when trazodone is combined with other serotonergic agents such as SSRIs, SNRIs, MAOIs, tramadol, or linezolid. Symptoms include hyperthermia, agitation, clonus, and diaphoresis. Combining trazodone with an MAOI is contraindicated [1].

Trazodone for Sleep vs. Depression: Different Expectations, Different Doses

The two most common uses of trazodone follow distinct timelines, and conflating them produces unrealistic patient expectations.

Sleep-Specific Dosing and Timeline

Doses of 25 to 100 mg at bedtime produce sedation within 30 to 60 minutes on the first night. Onset for sleep-specific benefit: night one to night three. The primary mechanism is H1 and 5-HT2A antagonism, not SERT inhibition. The Mendelson 2005 analysis confirms widespread prescribing for this indication based on tolerability and non-scheduling, not high-certainty RCT evidence [3].

Depression-Specific Dosing and Timeline

Antidepressant response requires doses of at least 150 mg per day and typically 2 to 4 weeks of adequate exposure. A 1994 RCT by Rickels et al. (Journal of Clinical Psychopharmacology, N=89) found trazodone 300 mg per day produced statistically significant HAMD-17 improvement over placebo by week 3, with continued separation at week 6 [10]. Starting at 75 mg and titrating too slowly delays reaching the therapeutic range and may falsely suggest non-response.

A Clinical Decision Framework: Is Trazodone Working?

Use these four checkpoints to assess response during the first month.

Day 3 (sleep target): Is sleep latency shorter? Is the patient sleeping through the night more often? If no sleep benefit at 50 mg by day 3, a dose increase to 75 to 100 mg is reasonable.

Day 7 (tolerability): Are sedation and dizziness manageable? If side effects are intolerable, consider a lower dose or switching to a different agent rather than pushing through.

Day 14 (dose adequacy for depression): Is the patient at 150 mg per day or higher? If still at the starting dose, titrate before concluding non-response.

Day 28 (antidepressant response assessment): Is there a 25 to 50% reduction in PHQ-9 or HAMD-17 scores? Partial response at week 4 supports continuing and titrating. No response at week 4 on an adequate dose (200 mg per day or higher) warrants reassessment of diagnosis, adherence, and potential augmentation or switch.

Drug Interactions Worth Knowing Before Week One

Cytochrome P450 3A4 (CYP3A4) metabolizes trazodone. CYP3A4 inhibitors such as ketoconazole, ritonavir, and clarithromycin raise trazodone plasma levels and increase sedation and adverse event risk. CYP3A4 inducers such as rifampin and carbamazepine reduce plasma levels and may blunt efficacy [1]. A complete medication review before starting trazodone catches these interactions before they become clinical problems.

CNS depressants including benzodiazepines, gabapentin, opioids, and alcohol add to sedation in an additive or synergistic fashion. Patients on any of these agents require lower starting doses and more careful monitoring in week one.

Special Populations: Adjustments to the Standard Timeline

Older Adults (Age 65 and Above)

Older patients metabolize trazodone more slowly, experience greater orthostatic hypotension, and face higher fall risk. The American Geriatrics Society Beers Criteria (2023 update) lists trazodone as a medication to use with caution in older adults due to orthostatic hypotension and CNS effects [11]. Starting at 25 to 50 mg at bedtime, titrating in 25 mg increments, and checking standing blood pressure at each increase is standard practice.

Hepatic Impairment

Trazodone clearance falls with hepatic dysfunction. No specific dose adjustment is listed in the FDA label, but clinical practice supports using the lowest effective dose and extending titration intervals in patients with moderate to severe hepatic impairment.

Pregnancy and Lactation

Trazodone is FDA Pregnancy Category C (historical classification). The current evidence is insufficient to establish safety in pregnancy, and the prescribing decision requires a benefit-risk discussion. Trazodone is excreted in breast milk at low levels; the LactMed database classifies it as "probably compatible" with breastfeeding but recommends monitoring the infant for sedation [12].

When to Contact Your Prescriber Before the Month Is Up

Certain findings should prompt same-day or emergency contact rather than waiting for the scheduled follow-up.

Call immediately for: priapism lasting more than two hours; symptoms of serotonin syndrome (fever, muscle rigidity, confusion, rapid heart rate); new or worsening suicidal thoughts (the FDA black-box warning on all antidepressants includes trazodone for this risk, particularly in patients under 24 during the first weeks of treatment) [1]; severe orthostatic dizziness with near-syncope; and irregular or fast heart rate, as trazodone carries a small QTc-prolongation signal at higher doses.

Contact within 24 to 48 hours for: side effects that are affecting work or daily function; no sleep benefit after three nights at 50 mg; and any rash, which may indicate hypersensitivity.